The art of the possible in approaching efficacy trials for COVID19 convalescent plasma

COVID-19 convalescent plasma (CCP) is widely used as a treatment. Although there are sufficient safety data, high-level evidence of efficacy is still lacking. We summarize here the results from randomized controlled trials (RCTs) published to date and analyze their flaws and biases. We then provide...

Descripción completa

Detalles Bibliográficos
Autores principales: Focosi, Daniele, Farrugia, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836915/
https://www.ncbi.nlm.nih.gov/pubmed/33130197
http://dx.doi.org/10.1016/j.ijid.2020.10.074
Descripción
Sumario:COVID-19 convalescent plasma (CCP) is widely used as a treatment. Although there are sufficient safety data, high-level evidence of efficacy is still lacking. We summarize here the results from randomized controlled trials (RCTs) published to date and analyze their flaws and biases. We then provide suggestions for the next round of CCP RCTs, discussing specification of CCP, therapeutic dose, timing, control arm, disease stage, and outcome measures.

Ejemplares similares